Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) EBT Margin: 2021-2025

Historic EBT Margin for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to -102.91%.

  • Rhythm Pharmaceuticals' EBT Margin rose 2937.00% to -102.91% in Q3 2025 from the same period last year, while for Sep 2025 it was -110.07%, marking a year-over-year increase of 11945.00%. This contributed to the annual value of -200.00% for FY2024, which is 3778.00% up from last year.
  • Rhythm Pharmaceuticals' EBT Margin amounted to -102.91% in Q3 2025, which was down 7.82% from -95.45% recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' EBT Margin peaked at 187,874.29% during Q1 2021, and registered a low of -14,748.54% during Q2 2021.
  • Over the past 3 years, Rhythm Pharmaceuticals' median EBT Margin value was -151.11% (recorded in 2025), while the average stood at -209.23%.
  • Over the last 5 years, Rhythm Pharmaceuticals' EBT Margin had its largest YoY gain of 1,425,414bps in 2022, and its largest YoY loss of 19,138,103bps in 2022.
  • Rhythm Pharmaceuticals' EBT Margin (Quarterly) stood at -2,798.84% in 2021, then skyrocketed by 231,542bps to -483.42% in 2022, then soared by 31,244bps to -170.99% in 2023, then soared by 6,728bps to -103.71% in 2024, then soared by 2,937bps to -102.91% in 2025.
  • Its last three reported values are -102.91% in Q3 2025, -95.45% for Q2 2025, and -151.11% during Q1 2025.